Matinas Biopharma Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 13 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly2.4M
Quarterly Net Loss Quarterly-1.9M
Quarterly Research and Development (R&D) Expenses Quarterly0.0
Quarterly General and Administrative (G&A) Expenses Quarterly1.9M
Watch Items
- NYSE American Continued Listing Compliance PlanTrigger: Acceptance or rejection of the remedial plan submitted by May 2, 2026Action: Monitor SEC filings and press releases for NYSE American's decision regarding the company's compliance plan to avoid delisting proceedings.
- MAT2203 Strategic Partnership or Asset MonetizationTrigger: Execution of a definitive licensing, partnership, or asset sale agreementAction: Evaluate the terms of any transaction to determine if it provides sufficient non-dilutive funding to resume clinical development or sustain operations.
- Going Concern Status and Cash RunwayTrigger: Cash depletion below critical operating levelsAction: Track quarterly cash burn rates and potential capital raises under the newly filed $150 million shelf registration statement.
Research as of 20 Jun 2026